Amy Hobeika
About
Amy Hobeika is a scholar working on Immunology, Oncology and Molecular Biology.
According to data from OpenAlex, Amy Hobeika has authored 90 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Immunology, 51 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Amy Hobeika's work include Immunotherapy and Immune Responses (55 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Immune Cell Function and Interaction (22 papers). Amy Hobeika is often cited by papers focused on Immunotherapy and Immune Responses (55 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Immune Cell Function and Interaction (22 papers). Amy Hobeika collaborates with scholars based in United States, China and United Kingdom. Amy Hobeika's co-authors include H. Kim Lyerly, Michael A. Morse, Timothy M. Clay, Takuya Osada, Howard M. Johnson, Donna Niedzwiecki, Alain Delcayre, Jean‐Bernard Le Pecq, Prem S. Subramaniam and Paul J. Mosca and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.
In The Last Decade
Amy Hobeika
86 papers receiving 4.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Amy Hobeika United States | 34 | 2.5k | 2.0k | 1.7k | 724 | 318 | 90 | 4.2k | ||
| Florence Faure France | 30 | 3.3k 1.3× | 2.2k 1.1× | 993 0.6× | 827 1.1× | 144 0.5× | 46 | 4.9k | ||
| Angelo A. Cardoso United States | 38 | 2.5k 1.0× | 2.0k 1.0× | 1.2k 0.7× | 349 0.5× | 332 1.0× | 86 | 5.3k | ||
| Hirokazu Matsushita Japan | 29 | 4.0k 1.6× | 1.3k 0.6× | 2.7k 1.6× | 367 0.5× | 253 0.8× | 90 | 5.3k | ||
| Ainhoa Arina United States | 28 | 2.7k 1.1× | 1.1k 0.5× | 2.3k 1.4× | 363 0.5× | 235 0.7× | 50 | 4.2k | ||
| Michael C. Schmid United Kingdom | 32 | 1.6k 0.7× | 1.6k 0.8× | 1.6k 1.0× | 591 0.8× | 214 0.7× | 53 | 4.1k | ||
| Timothy M. Clay United States | 41 | 3.2k 1.3× | 2.6k 1.3× | 2.2k 1.3× | 747 1.0× | 796 2.5× | 97 | 5.9k | ||
| Benjamin Weide Germany | 29 | 2.0k 0.8× | 1.4k 0.7× | 2.1k 1.3× | 216 0.3× | 323 1.0× | 74 | 3.6k | ||
| Valérie Dutoit Switzerland | 35 | 2.2k 0.9× | 1.2k 0.6× | 1.2k 0.7× | 271 0.4× | 181 0.6× | 83 | 3.3k | ||
| Sebastian Kreiter Germany | 29 | 2.9k 1.2× | 2.6k 1.3× | 1.9k 1.1× | 259 0.4× | 661 2.1× | 64 | 4.6k | ||
| Wenru Song United States | 21 | 2.1k 0.8× | 1.2k 0.6× | 2.1k 1.3× | 308 0.4× | 643 2.0× | 33 | 3.8k |
Countries citing papers authored by Amy Hobeika
Since
Specialization
Citations
This map shows the geographic impact of Amy Hobeika's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Hobeika with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Hobeika more than expected).
Fields of papers citing papers by Amy Hobeika
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Amy Hobeika. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Hobeika. The network helps show where Amy Hobeika may publish in the future.
Co-authorship network of co-authors of Amy Hobeika
This figure shows the co-authorship network connecting the top 25 collaborators of Amy Hobeika. A scholar is included among the top collaborators of Amy Hobeika based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Hobeika. Amy Hobeika is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lei, Gangjun, Xiaoyi Yang, Tao Wang, et al.. (2024). Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer. Human Vaccines & Immunotherapeutics. 20(1). 2309693–2309693.
2.
Rebbeck, Clare A., Jian Xian, Susanne Bornelöv, et al.. (2022). Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. Nature Communications. 13(1). 3399–3399.
3.
Wang, Shuo, Fang Tong, Xiaoguang Qiu, et al.. (2021). Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. International Journal of Radiation Oncology*Biology*Physics. 111(2). 479–490.
4.
Wang, Xiaoli, Shuo Wang, Michael A. Morse, et al.. (2019). Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. Journal of Thrombosis and Thrombolysis. 47(4). 505–511.
5.
Crosby, Erika J., William R. Gwin, Kimberly Blackwell, et al.. (2019). Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. Clinical Cancer Research. 25(9). 2725–2736.
6.
Qiao, Guoliang, Xiaoli Wang, Lei Zhou, et al.. (2018). Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. Clinical Cancer Research. 25(5). 1494–1504.
7.
Zhao, Yanhua, Yang Song, Xin Zhou, et al.. (2018). Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS). Clinical & Translational Oncology. 21(6). 721–728.
8.
Osada, Takuya, Zachary C. Hartman, Jun-Ping Wei, et al.. (2018). Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Research. 20(1). 90–90.
9.
Jiang, Ni, Guoliang Qiao, Xiaoli Wang, et al.. (2017). Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clinical Cancer Research. 23(17). 5066–5073.
10.
Osada, Takuya, William R. Gwin, Michael A. Morse, et al.. (2017). In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clinical Cancer Research. 23(24). 7531–7542.
11.
Zhou, Xinna, Guoliang Qiao, Xiaoli Wang, et al.. (2017). CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. Cancer Chemotherapy and Pharmacology. 81(2). 365–372.
12.
Hamilton, Erika, Kimberly Blackwell, Amy Hobeika, et al.. (2012). Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. Journal of Translational Medicine. 10(1). 28–28.
13.
Morse, Michael A., Robert Chapman, John D. Powderly, et al.. (2011). Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients. Clinical Cancer Research. 17(14). 4844–4853.
14.
Hartman, Zachary C., Jun-Ping Wei, Takuya Osada, et al.. (2010). An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity. Clinical Cancer Research. 16(5). 1466–1477.
15.
Morse, Michael A., Jun-Ping Wei, Zachary C. Hartman, et al.. (2009). Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of Cancer. 126(12). 2893–2903.
16.
Osada, Takuya, David S. Hsu, Scott A. Hammond, et al.. (2009). Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. British Journal of Cancer. 102(1). 124–133.
17.
Hobeika, Amy, Takuya Osada, Delila Serra, et al.. (2008). Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy. 10(3). 289–302.
18.
Osada, Takuya, Timothy Clay, Amy Hobeika, H. Kim Lyerly, & Michael A. Morse. (2005). NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunology Immunotherapy. 55(9). 1122–1131.
19.
Kominsky, Scott L., et al.. (2000). Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.. PubMed. 60(14). 3904–8.
20.
Kominsky, Scott L., Howard M. Johnson, Taishi Tanabe, et al.. (1998). IFNγ inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1. Oncogene. 17(23). 2973–2979.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Florence Faure Breakdown of academic impact, for papers by Angelo A. Cardoso Breakdown of academic impact, for papers by Hirokazu Matsushita Breakdown of academic impact, for papers by Ainhoa Arina Breakdown of academic impact, for papers by Michael C. Schmid Breakdown of academic impact, for papers by Timothy M. Clay Breakdown of academic impact, for papers by Benjamin Weide Breakdown of academic impact, for papers by Valérie Dutoit Breakdown of academic impact, for papers by Sebastian Kreiter Breakdown of academic impact, for papers by Wenru Song